Playing God with the fates of cellsDreams of simple, reliable and scalable processes for the much-hyped cell therapy market have generated demand for cost-effective, GMP-compliant manufacturing methods. The drug-screening market is also … more ➔
The biotech boost – when, if not now? Despite the threat of a looming climate catastrophe, low oil prices and giant industrial conglomerates addicted to fossil resources continue to stifle industrial biotechnology products and innovation. … more ➔
Setting trends with eco-fashion Enzymes have been used widely for years to bleach textiles or shrink wool. However, the clothing sector is one of the world’s most polluting industries. And now fashion labels are turning increasingly … more ➔
Council presses EC to decide on genome editing After years of regulatory deadlock concerning political decision making on genome-edited and genetically targeted mutational breeding, the European Council has demanded that the European Commission … more ➔
New players to step into the AMR fieldDespite challenging markets new players are entering the field to advance drug development in the fight against antimicrobial resistance. more ➔
The AMR business (Part II)SMEs active in antibiotic development are trying to adapt to the uncertain AMR business. Meanwhile, the European IMI AMR accelerator kicked off. more ➔
The AMR business (Part I)Antibiotic developers struggle with uncertain market conditions, weak reimbursement schemes and low turnover once a drug is approved. Experts are trying to figure out the best way to balance push and … more ➔
The Dawn of Malaria’s Doom Although it has only been shown to provide partial protection, the first-ever malaria vaccine is in testing in Africa – and there are many more hopefuls in the pipeline. Will we soon eradicate … more ➔
Controlled human malaria infection trials Tackling the malaria pathogen P. falciparum has been complex, due to rapid development of resistance. A new compound targets liver stages of the parasite and, thus, provides a new mode of action to … more ➔
Making every cent in testing count It’s no easy task to develop medications that are effective and safe to use. The pharmaceutical industry loses billions every year due to safety-related attrition during the drug discovery process. … more ➔
![Source: Eric Erbe, Christopher Pooley [Public domain]](https://european-biotechnology.com/wp-content/uploads/2024/04/2019_11_05_staphyllo_sw-300x169.jpg "2019_11_05_staphyllo_sw.jpg")
